Lanean...
Alternate-day dosing of linagliptin in type 2 diabetes patients controlled on once daily dose: A case series
Linagliptin, a dipeptidyl peptidase 4 (DPP 4) inhibitor with a long terminal half life, significantly inhibits the DPP 4 enzyme at a steady state up to 48 h after the last dose. The present case series examined the hypothesis that linagliptin retains its efficacy during alternate day dosing in type...
Gorde:
| Argitaratua izan da: | Indian J Endocrinol Metab |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Medknow Publications & Media Pvt Ltd
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4911851/ https://ncbi.nlm.nih.gov/pubmed/27366728 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2230-8210.183468 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|